Abstract
We read with interest the results of a phase 2 randomized controlled PREMIUM trial by Usmani et al 1 Usmani N Ghosh S Sanghera KP et al. Metformin for prevention of anthropometric and metabolic complications of androgen deprivation therapy in prostate cancer patients receiving radical radiotherapy: A phase II randomized controlled trial. Int J Radiat Oncol Biol Phys. 2023; 115: 317-326 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar investigating the potential benefits of metformin in preventing metabolic complications of androgen deprivation therapy in patients with prostate cancer undergoing radiation therapy. While the authors comprehensively reported the anthropometric, metabolic, and biochemical changes between the metformin and placebo arms, we still have some concerns about the addition of metformin in patients with cancer who do not have diabetes. In Reply to Hsu and ShuengInternational Journal of Radiation Oncology, Biology, PhysicsVol. 116Issue 3PreviewWe are grateful for the interest and comments1 regarding the results of our phase 2 randomized controlled trial (PREMIUM: NCT01996696) which investigated the role of metformin in preventing metabolic complications of androgen deprivation therapy (ADT) in patients with prostate cancer undergoing curative radiation therapy.2 Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
